Menstrual Cramps Treatment Market, By Drug Class (Analgesics, Anticholinergics, Non-steroidal anti-inflammatory drugs, Haematinics, and Others (Progestins, Among others)), By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), By Route of Administrati

Menstrual cramps (dysmenorrhea) are throbbing or cramping pains in the lower abdomen. Many women have menstrual cramps just before and during their menstrual periods. Conditions such as endometriosis or uterine fibroids can cause menstrual cramps. Symptoms occurred like aching pain in lower abdomen, a feeling of pressure in belly, pain in hips, lower back, and inner thighs. To treat menstrual cramps, over-the-counter pain relievers such as NSAID’s like ibuprofen (Advil), Naproxen sodium (Aleve) are used. Hormonal antagonists drugs such as MYFEMBREE (Pfizer) also used for the treatment of menstrual cramps.

Market Dynamics

Market players in the market are focusing on ncreasing inorganic strategies such as collaboration for menstrual cramp treatment is expected to drive the the global menstrual cramp market growth over the forecast period. For instance, on April 10, 2018, AbbVie, a global research and development-based biopharmaceutical company, and Neurocrine Biosciences, announced PDUFA (Prescription Drug User Fee Act) for Elagolix in endometriosis-associated pain.. Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is administered orally, and is a short-acting molecule that blocks endogenous GnRH receptors in the pituitary gland.

Increasing prevalence of menstrual cramps is expected to drive the market growth over the forecast period. For instance, on January 14, 2022, article published by MDPI, stated that a study was conducted in Europe’s Romania in prospective, analytical, observational and took place between 7 November 2019 and 30 January 2020. This study included a population of 1720 from five university centers throughout the country. Out of 1,720 participants, 1,349 (78.4%) had dysmenorrhea. The prevalence of dysmenorrhea, ranging from 16% to 91% has been reported. The most widely used drugs were non-steroidal anti-inflammatory drugs, utilized by 741 students (54.9%) has been reported.

Moreover, according to article published by International Journal of Womens Health, a study was conducted in Southern Ethiopia, the prevalence of primary dysmenorrhea among all the female students is 70% of population who reported.

Key features of the study:

• This report provides in-depth analysis of the global menstrual cramps treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global menstrual cramps treatment market based on the following parameters company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer Inc., Ingelheim International GmbH., Bayer AG, , Cipla Inc, Teva Pharmaceutical Industries Ltd., Sanofi, Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Ltd, Almatica Pharma LLC., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Eisen Pharmaceutical Co. (Pvt.) Ltd., Emcure Pharmaceuticals, AbbVie., Sparsha Pharma International Pvt Ltd, Hope Medicine (Nanjing) Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global menstrual cramps treatments market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global menstrual cramps treatments market

• Global Menstrual Cramp Treatment Market, By Drug Class:
• Analgesics
• Anticholinergic
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Haematinics
• Others (Progestins, Among others)
• Global Menstrual Cramp Treatment Market, By Type:
• Primary Dysmenorrhea
• Secondary Dysmenorrhea
• Global Menstrual Cramp Treatment Market, By Route of Administration:
• Oral
• Injectable
• Topical
• Others (Intrauterine, Others)
• Global Menstrual Cramp Treatment Market, By Dosage Form:
• Tablet
• Capsules
• Suspension
• Others (Transdermal Patch, Among others)
• Global Menstrual Cramp Treatment Market, By Distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Menstrual Cramps Treatment Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Pfizer Inc.
• Ingelheim International GmbH PerkinElmer Inc.
• Bayer AG
• Abbott.
• Cipla Inc
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Johnson & Johnson Services, Inc.
• Dr. Reddy’s Laboratories Ltd
• Almatica Pharma LLC.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Eisen Pharmaceutical Co. (Pvt.) Ltd.
• Emcure Pharmaceuticals
• AbbVie.
• Sparsha Pharma International Pvt Ltd.
• Hope Medicine (Nanjing) Co., Ltd